- Modern Pathology（Argani、Aatur Singhi 等，约翰斯·霍普金斯、匹兹堡大学）：多中心 334 例肝胆肿瘤全转录组测序（含 CBCA 10 例、肝内胆管癌 163 例），另以 445 例独立队列验证 GATA4 免疫组化。
- NIPBL::NACC1 融合见于全部 10 例 CBCA，其余 324 例均阴性；CBCA 单独成簇、最靠近 iCCA，差异表达基因最多。
- GATA4 上调，靶基因 INHA 倍数变化最大，可解释 CBCA 的抑制素 A 免疫表型；GATA4 蛋白过表达：CBCA 6/6、iCCA 2%、HCC 0/278。细胞起源分析为中间型胆管祖细胞状态，免疫几乎完全排斥。
- 读片提示：抑制素 A 阳性的实性/小梁状肝内肿瘤，加做 GATA4 有助支持 CBCA、排除 HCC；作者认为结果支持保留「胆管母细胞型」命名。本站仅获摘要。
收录范围：PubMed 摘要中英对照。出版社页面被 Cloudflare 拦截，本站未获全文与图表。
摘要
胆管母细胞型胆管癌（CBCA）是一种罕见的肝胆肿瘤，以 NIPBL::NACC1 融合为定义特征。其细胞起源和命名仍未定论，部分研究者主张将其重新归类为融合阳性的肝癌，而非胆管癌的一个独特亚型。本研究采用全转录组测序（WTS），确定 CBCA 相对于其他肝胆恶性肿瘤的转录程序和分化状态。
共对来自多家机构的 334 例肝胆肿瘤进行 WTS，涵盖 8 个诊断类别，其中 CBCA 10 例、肝内胆管癌（iCCA）163 例。进行了聚类、差异表达、基因集富集、免疫反卷积和细胞起源分析，并在 445 例独立队列中验证 GATA4 免疫组化。
10 例 CBCA 均检出 NIPBL::NACC1 融合基因，其余 324 例肿瘤均未检出。诊断类别解释了 52.7% 的转录组变异（p=0.001）；CBCA 形成一个独立的聚类，与 iCCA 最接近，但基因层面重叠有限；其差异表达基因数多于任何其他类别（与其余全部类别合并比较，n=1,451）。GATA4 上调（log2FC=3.23，p<0.001），33 个 GATA4 靶基因中 14 个上调，其中 INHA 倍数变化最大；相应地，GATA4 蛋白过表达见于 6/6 例 CBCA、2% 的 iCCA 和 0/278 例 HCC。突触与神经内分泌程序是富集最显著的通路；细胞起源分析将 CBCA 定位于中间型胆管祖细胞状态，其双潜能指数（Bipotency Index）在各类别中最高（p≤0.001），并几乎完全免疫排斥。
综上，这些发现确定了 NIPBL::NACC1 下游的 GATA4-INHA 转录程序，可解释 CBCA 的抑制素 A 免疫表型。这种胆管祖细胞状态支持「胆管母细胞型」的命名，而非肝细胞癌起源，GATA4 免疫组化在蛋白水平证实了这一点。
- Modern Pathology (Argani, Aatur Singhi and colleagues, Johns Hopkins and UPMC): whole transcriptome sequencing of 334 hepatobiliary neoplasms from several institutions (10 CBCA, 163 iCCA), with GATA4 IHC validated in an independent cohort of 445 cases.
- NIPBL::NACC1 was found in all 10 CBCA and none of the other 324 tumours; CBCA formed a discrete cluster nearest iCCA and had the most differentially expressed genes.
- GATA4 was upregulated, with INHA showing the largest fold change among its targets, explaining the inhibin A immunophenotype; GATA4 protein was overexpressed in 6/6 CBCA, 2% of iCCA and 0/278 HCC. Cell-of-origin analysis placed CBCA in an intermediate biliary progenitor state with near-complete immune exclusion.
- Practice point: in an inhibin A-positive solid/trabecular intrahepatic tumour, GATA4 IHC can support CBCA over HCC; the authors argue for keeping the cholangioblastic designation. Abstract only.
Scope: the PubMed abstract. The publisher page was blocked by Cloudflare for our fetcher, so the full text and figures were not obtained.
Abstract
Cholangioblastic cholangiocarcinoma (CBCA) is a rare hepatobiliary neoplasm defined by the NIPBL::NACC1 fusion. Its cell of origin and nomenclature remain unresolved, and some investigators favor reclassification as a fusion-positive hepatic carcinoma rather than a distinctive cholangiocarcinoma variant. We used whole transcriptome sequencing (WTS) to define the CBCA transcriptional program and differentiation state relative to other hepatobiliary malignancies.
In total, 334 hepatobiliary neoplasms were subjected to WTS from multiple institutions, spanning eight diagnostic categories including 10 CBCA and 163 intrahepatic cholangiocarcinoma (iCCA). Clustering, differential expression, gene set enrichment, immune deconvolution, and cell-of-origin analyses were performed, and GATA4 immunohistochemistry was validated on an independent cohort of 445 cases.
The NIPBL::NACC1 fusion gene was identified in all 10 CBCA and in none of the remaining 324 neoplasms. Diagnostic category accounted for 52.7% of transcriptomic variance (p=0.001), and CBCA formed a discrete cluster nearest iCCA despite limited gene-level overlap, and harbored more differentially expressed genes than any category (n=1,451 vs. all combined). GATA4 was upregulated (log2FC=3.23, p<0.001), with upregulation of 14 of 33 GATA4 target genes including INHA (largest fold change), corresponding to GATA4 protein overexpression in 6 of 6 CBCA, 2% of iCCA, and 0 of 278 HCC. Synaptic and neuroendocrine programs were the most enriched pathways, and cell-of-origin analysis placed CBCA in an intermediate biliary progenitor state with the highest Bipotency Index of any category (p≤0.001) and near-complete immune exclusion.
Together, these findings define a GATA4-INHA transcriptional program downstream of NIPBL::NACC1 that accounts for the inhibin A immunophenotype of CBCA. This biliary progenitor state supports the cholangioblastic designation over a hepatocellular carcinoma origin, confirmed at the protein level by GATA4 immunohistochemistry.